A stepwise approach for pharmacists: Cardiovascular risk reduction with novel antihyperglycemic agents in patients with type 2 diabetes and atherosclerotic cardiovascular disease

Abstract

Get full access to this article

View all access options for this article.

References

Das

Everett

Birtcher

, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.J Am Coll Cardiol 2018;72(24):3200-23.

Puymirat

Taldir

Aissaoui

, et al. Use of invasive strategy in non-ST-segment elevation myocardial infarction is a major determinant of improved long-term survival: FAST-MI (French Registry of Acute Coronary Syndrome). JACC Cardiovasc Interv 2012;5(9):893-902.

Law

Watt

Wald

The underlying risk of death after myocardial infarction in the absence of treatment. Arch Intern Med 2002;162(21):2405-10.

Bata

Gregor

Wolf

, et al. Trends in five-year survival of patients discharged after acute myocardial infarction. Can J Cardiol 2006;22(5):399-404.

Curtis

Schreiner

Wang

, et al. All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients. J Am Coll Cardiol 2009;54(10):903-7.

Mehta

Bainey

Cantor

, et al. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology focused update of the guidelinesfor the use of antipletelet therapy. Can J Cardiol 2018;34(3):214-33.

Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2018;42(1):S1-S325.

Zinman

Wanner

Lachin

, et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-29.

Gerstein

Colhoun

Dagenais

, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394(10193):121-30.

10.

Hernandez

Green

Janmohamed

, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018;392(10157):1519-29.

11.

Neal

Perkovic

Mahaffey

, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-57.

12.

Marso

Daniels

Brown-Frandsen

, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-22.

13.

Marso

Bain

Consoli

, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375(19):1834-44.

14.

Boehreinger Ingelheim Canada Ltd. Jardiance product monograph. Burlington, Ontario. Available: https://www.boehringer-ingelheim.ca/sites/ca/files/documents/jardiancepmen.pdf (accessed Aug. 11, 2019).

15.

Janssen Inc. Invokana product monograph. Toronto, Ontario. Available: https://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/invokana_cpm.pdf (accessed Aug. 11, 2019).

16.

Novo Nordisk Canada Inc. Victoza product monograph. Mississauga, Ontario. Available: https://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/victoza-product-monograph.pdf (accessed Aug. 29, 2019).

17.

Vardeny

Vaduganathan

Practical guide to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists. JACC Heart Fail 2019;7(2):169-72.

18.

Diabetes Canada Clinical Practice Guidelines Expert Committee. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. Can J Diabetes 2020;44(7):575-91.

19.

Cosentino

Grant

Aboyans

, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabets, and cardiovacular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J 2019;41(2):255-323.

20.

Wiviott

Raz

Bonaca

, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2018;380(4):347-57.

21.

Cannon

Kumbhani

Bhatt

. Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial—American College of Cardiology. American College of Cardiology. June 16, 2020. Available: https://www.acc.org/latest-in-cardiology/clinical-trials/2020/06/16/11/24/vertis (accessed Jun. 19, 2020).

22.

Marck Canada Inc. Steglatro product monograph. Kirkland, Quebec. Available: https://www.merck.ca/static/pdf/STEGLATRO-PM_E.pdf (accessed Oct. 30, 2020).

23.

AstraZenece Canada Inc. Forxiga product monograph. Mississaugua, Ontario. Available: https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/forxiga-product%20monograph-en.pdf (accessed Oct. 30, 2020).

24.

Diabetes Pharmacists Network. SGLT2 inhibitors practice tool: Banting & Best Diabetes Centre. Published February 2018. Updated Oct 2018. Available: https://www.diabetespharmacistsnetwork.ca/download/sglt2-practice-tool/.

25.

Rosenstock

Ferrannini

Euglycemic diabetic ketoacidosis: a predictable, detectable and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015;38:1638-42.

26.

Handelsman

Henry

Bloomgarden

, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocrine Pract 2016;22(6):753-62.

27.

Regier

LeBras

Diabetes treatment: glycemic management in T2DM. RxFiles Drug Comparison Charts. Saskatoon, SK: Saskatoon Health Region; 2019. p 40-42. Available: rxfiles.ca/RxFiles/uploads/documents/members/cht-diabetes.pdf (accessed Nov. 5, 2019).

28.

Williams

Ahmed

1224-P: improving compliance with SGLT2 inhibitors by reducing the risk of genital mycotic infections: the outcomes of personal hygiene advice. Diabetes 2019;68(suppl 1).